These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 31115011

  • 1. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
    Jiang GB, Fang HY, Tao DY, Chen XP, Cao FL.
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
    [Abstract] [Full Text] [Related]

  • 2. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    He Y, Xie H, Yu P, Jiang S, Wei L.
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
    [Abstract] [Full Text] [Related]

  • 3. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R, Sun S, Ji F, Liu C, Lin H, Xie L, Yang H, Tang W, Zhou Y, Xu J, Li P.
    Cell Physiol Biochem; 2017 Dec; 43(2):465-480. PubMed ID: 28934754
    [Abstract] [Full Text] [Related]

  • 4. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C, Lin X, Wang Y, Liu X, Xiao Y, Liu J, Snijders AM, Wei G, Mao JH, Zhang P.
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [Abstract] [Full Text] [Related]

  • 5. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
    Wang ZL, Fan ZQ, Jiang HD, Qu JM.
    Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK, Manavathi B.
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [Abstract] [Full Text] [Related]

  • 8. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
    Li JM, Yang F, Li J, Yuan WQ, Wang H, Luo YQ.
    Med Sci Monit; 2020 Aug 07; 26():e925298. PubMed ID: 32764530
    [Abstract] [Full Text] [Related]

  • 9. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H, Lu W.
    Oncotarget; 2016 Apr 26; 7(17):24510-26. PubMed ID: 27014910
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells.
    Nonpanya N, Prakhongcheep O, Petsri K, Jitjaicham C, Tungsukruthai S, Sritularak B, Chanvorachote P.
    Anticancer Res; 2020 Sep 26; 40(9):4989-4999. PubMed ID: 32878787
    [Abstract] [Full Text] [Related]

  • 13. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function.
    Zhang S, Wang Y.
    J Biochem Mol Toxicol; 2020 Oct 26; 34(10):e22560. PubMed ID: 32627280
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J, Bai X, Feng X, Ni J, Beretov J, Graham P, Li Y.
    BMC Cancer; 2019 Jun 24; 19(1):618. PubMed ID: 31234823
    [Abstract] [Full Text] [Related]

  • 15. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W, Wei Y, Li Y, Yin Y, Yuan W, Yang Y, Zhao W, Wu J.
    Oncol Rep; 2017 Sep 24; 38(3):1815-1821. PubMed ID: 28737828
    [Abstract] [Full Text] [Related]

  • 16. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
    Ogunwobi OO, Liu C.
    Clin Exp Metastasis; 2011 Dec 24; 28(8):721-31. PubMed ID: 21744257
    [Abstract] [Full Text] [Related]

  • 17. CD146 Promotes EMT-Mediated Migration and Invasion of NSCLC via PI3K/Akt Signaling Pathway.
    Wei N, Wu X, Yu Y, Zhou H, Cui K, Zhao X, Zhang X.
    Front Biosci (Landmark Ed); 2024 Apr 08; 29(4):140. PubMed ID: 38682195
    [Abstract] [Full Text] [Related]

  • 18. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W, Ping W, Tian Y, Zou W, Liu J, Zu Y.
    Cell Physiol Biochem; 2018 Apr 08; 51(5):2160-2171. PubMed ID: 30522099
    [Abstract] [Full Text] [Related]

  • 19. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B, Ding CM, Li YX, Peng JC, Geng N, Qin WW.
    Oncol Rep; 2018 Mar 08; 39(3):1227-1234. PubMed ID: 29344640
    [Abstract] [Full Text] [Related]

  • 20. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
    Farhan M, Malik A, Ullah MF, Afaq S, Faisal M, Farooqi AA, Biersack B, Schobert R, Ahmad A.
    Int J Mol Sci; 2019 Feb 13; 20(4):. PubMed ID: 30781783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.